Fishawack opens US office in San Francisco

pharmafile | September 2, 2014 | News story | Medical Communications US, comms, communications, fishawack, san francisco 

Medical communications firm Fishawack has opened a new office in San Francisco in the US.

Under its flagship Fishawack Communications brand and operating from Spear Tower at One Market Street, which is close to San Francisco’s Bay Bridge, the team will now support clients based on the west coast of the country.

The firm says this completes a further step in its strategy to provide access to global scientific, medical comms, and pharmacovigilance support services in key locations for the pharma and biopharma industries, with Fishawack now having offices in the UK, Switzerland, and now both sides of the US.

“Following the expansion of our east coast US team earlier this year when JK Associates joined the group, the next logical step was to invest in an office on the west coast to support our clients located there,” explains Oliver Dennis, chief executive of Fishawack.

“The San Francisco team will provide west coast clients with local access to Fishawack’s wider US team of 50 staff and to our global organisation,” adds Tim Collinson, senior director, editorial services, at Fishawack Communications.

John ‘Zeke’ Czekanski, the president of Fishawack’s US operations says: “Tim’s medical communications experience includes four years in North America (New Jersey, US, and Toronto, Canada), and senior positions with Fishawack within both its UK and Swiss operations.

“He is the ideal person to establish the San Francisco office, ensuring we support our clients effectively, whether they’re in the Bay Area or farther afield, and to optimise the connections with the rest of the group. To reflect the importance we are placing on Tim’s role in our US organisation, he is now a member of our US leadership team.”

Brett Wells

Related Content

Expansion for first FDA-approved video game for ADHD treatment

Akili Interactive has announced the expansion of its prescription video game treatment, EndeavorRx, with the …

New warning added to J&J vaccine in US

The FDA has made the decision to add a warning to the fact sheet for …


CHMP issue positive opinion for Incyte and MorphoSys’ tafasitamab

Incyte and MorphoSys have announced that the EMA’s Committee for Medicinal Products for Human Use …

Latest content